Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.76, $0.68 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.69 billion versus the consensus estimate of $2.58 billion.

GUIDANCE:

Vertex Pharma sees FY2024 revenue of $10.55-10.75 billion, versus the consensus of $10.718 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.